Aridis Pharmaceuticals is focused on the development of novel, differentiated therapies for infectious diseases. The Company’s anti-infective product portfolio includes three clinical stage monoclonal antibodies (mAb) and three additional preclinical anti-infective drug candidates. This suite of anti-infective monoclonal antibodies is highly differentiated from conventional antibiotics, effective against all antibiotic resistant strains which the mAbs are directed against, and offers opportunities to profoundly impact current approaches to infection control.